Literature DB >> 29345598

Dolutegravir-Related Neurological Adverse Events: A Case Report of Successful Management with Therapeutic Drug Monitoring.

Francois Parant1, Patrick Miailhes1, Florence Brunel1, Marie-Claude Gagnieu1.   

Abstract

OBJECTIVE: Dolutegravir (DTG), a highly effective second-generation HIV integrase inhibitor with high genetic barrier to resistance, has shown excellent tolerability and safety profiles in clinical trials. However, some patients may experience neurological or psychiatric adverse effects leading to DTG discontinuation. CASE REPORT: This report describes a case of 29-year-old woman who developed neurological adverse events after starting the DTG-based antiretroviral therapy. Serum DTG concentrations were supratherapeutic which has required a dosing interval adjustment. The findings of this case report suggest that Therapeutic Drug Monitoring might be useful in individuals expressing unusual DTG pharmacokinetics. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Entities:  

Keywords:  Dolutegravir; INSTI.; adverse events; antiretroviral; pharmacokinetics; therapeutic drug monitoring

Mesh：

Substances：

Year:  2018        PMID： 29345598     DOI： 10.2174/1574886313666180116124046

Source DB:  PubMed          Journal:  Curr Drug Saf        ISSN： 1574-8863


  6 in total

1.  Reversibility of Central Nervous System Adverse Events in Course of Art.

Authors:  Lucia Taramasso; Giancarlo Orofino; Elena Ricci; Barbara Menzaghi; Giuseppe Vittorio De Socio; Nicola Squillace; Giordano Madeddu; Francesca Vichi; Benedetto Maurizio Celesia; Chiara Molteni; Federico Conti; Filippo Del Puente; Eleonora Sarchi; Goffredo Angioni; Antonio Cascio; Carmela Grosso; Giustino Parruti; Antonio Di Biagio; Paolo Bonfanti
Journal:  Viruses       Date:  2022-05-11       Impact factor: 5.818

2.  Older Age is Associated with Higher Dolutegravir Exposure in Plasma and Cerebrospinal Fluid of People Living with HIV.

Authors:  Andrea Calcagno; José Moltó; Alberto Borghetti; Cristina Gervasoni; Maurizio Milesi; Marta Valle; Valeria Avataneo; Chiara Alcantarini; Francesc Pla-Junca; Mattia Trunfio; Antonio D'Avolio; Simona Di Giambenedetto; Dario Cattaneo; Giovanni Di Perri; Stefano Bonora
Journal:  Clin Pharmacokinet       Date:  2021-01       Impact factor: 6.447

3.  ABCG2 Deficiency Does Not Alter Dolutegravir Metabolism and Pharmacokinetics.

Authors:  Junjie Zhu; Xin Tian; Amina I Shehu; Deborah K McMahon; Xiaochao Ma
Journal:  J Pharmacol Exp Ther       Date:  2020-04-17       Impact factor: 4.030

4.  Patterns of efavirenz use as first-line antiretroviral therapy in the United States: 1999-2015.

Authors:  Angela M Bengtson; Brian W Pence; Ellen F Eaton; Jessie K Edwards; Joseph J Eron; William C Mathews; Katie Mollan; Richard D Moore; Connall O'Cleirigh; Elvin Geng; Michael J Mugavero
Journal:  Antivir Ther       Date:  2018

5.  Psychiatric Disorders after Switching to Dolutegravir: A Case Report of a 59-Year-Old Virosuppressed HIV-1 Positive Woman.

Authors:  Daniele Mengato; Raffaella Binazzi; Ivan Unterholzner; Elke M Erne; Alicia Tavella
Journal:  Case Rep Infect Dis       Date:  2020-04-14

Review 6.  Update on Adverse Effects of HIV Integrase Inhibitors.

Authors:  Agnieszka Kolakowska; Anaenza Freire Maresca; Intira Jeannie Collins; Johann Cailhol
Journal:  Curr Treat Options Infect Dis       Date:  2019-11-16
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.